<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918229</url>
  </required_header>
  <id_info>
    <org_study_id>BPI-01 (USA)</org_study_id>
    <nct_id>NCT00918229</nct_id>
  </id_info>
  <brief_title>Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects</brief_title>
  <official_title>One-arm, Multi-center, International Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioProtect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioProtect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Goal

      The study's primary goal is to assess the safety of the BioProtect biodegradable balloon
      implant and implantation procedure, in prostate cancer subjects undergoing routine radiation
      therapy (XRT) treatment. Safety of the BioProtect device will be assessed by reporting
      adverse events.

      Secondary Goal

      The study's secondary goal is to evaluate the effectiveness of the BioProtect biodegradable
      balloon implant in prostate cancer subjects undergoing routine XRT treatment. Effectiveness
      will be assessed in terms of increased distance between anterior rectal wall and prostate and
      noticeable reduction of isodose to the rectum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint Parameters

      The incidence of unexpected serious adverse events related to BioProtect's SpaceGuard balloon
      implant and/or implantation procedure:

        1. Serious Adverse Events related to the BioProtect balloon and/or implantation procedure
           were defined by the Clinical Trials.gov definition of a serious adverse event. Serious
           Adverse Events will be documented in Serious Adverse Event Form.

        2. Adverse Events related to the BioProtect balloon and/or implantation procedure. Adverse
           Events were documented in Adverse Event Form.

        3. Subjective discomfort related to the balloon and implantation procedure were assessed by
           a pain analogue scale.

      Secondary Endpoint Parameters A 10% decrease or greater of the average rectal doses at V50 in
      at least 75% of the subjects after balloon implantation as compared to the doses at V50
      before the balloon implantation. This was measured by routine Dose Volume Histogram (DVH) per
      local hospital practice and according to the instructions regarding anatomical landmarks
      delineated in this protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum Receiving at Least 70 Gy.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated in subjects with prostate cancer who underwent radiotherapy by means of IMRT and who received the ProSpace, with individual patient success defined as a reduction of at least 25% of the volume of the rectum receiving greater or equal to 70 Gy (VRectum70) when compared to pre-implantation values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Occurrence of Grade 2 or Greater Rectal Adverse Event or Procedure Related Adverse Events.</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the rate of occurrence of rectal adverse events and implantation procedure related adverse events in balloon and control groups.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>balloon implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>implantation of an absorbable perirectal spacer balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon implant</intervention_name>
    <description>Absorbable perirectal spacer implantation</description>
    <arm_group_label>balloon implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Balloon implantation</intervention_name>
    <description>Implantation of the balloon between the prostate and the anterior rectal wall</description>
    <arm_group_label>balloon implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male above 45 years old and less than 85.

          -  Diagnosed locally confined prostate cancer per hospital practice and definitions for
             local confined prostate cancer.

          -  Subject is scheduled for only localized prostate XRT treatments

          -  Zubrod performance status 0-1; or Karnofsy &gt;80

          -  Blood CBC and biochemistry up to two weeks before screening demonstrating:

               -  Platelets ≥ 100,000 cells/mm3

               -  Hemoglobin ≥ 10.0 g/dl

               -  Normal values of electrolytes (sodium, potassium, calcium)

               -  Normal values of the PT, PTT and INR tests.

          -  Peak Uroflow rate ≥ 13ml/sec

          -  Residual Urine volume Test result &lt; 150 ml

          -  Urinalysis (RBC, WBC) and urine culture

          -  Subject able to comprehend and give informed consent for participation in this study
             and are considered by the investigator to have good compliance for the study.

        Exclusion Criteria:

          -  Any prior prostate resection with a compliant prostate urethra as assessed by
             transrectal ultrasound (TRUS)

          -  Prior radical prostatectomy

          -  Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for
             prostate cancer

          -  Suspected extension of the prostate tumour toward the rectum as evidenced by
             acceptable imaging modalities used in the study site

          -  Prior surgical procedure involving peri-rectal and peri-prostatic area

          -  Prior radiotherapy to the pelvis, including brachytherapy at the same body organ

          -  Unstable angina

          -  Congestive heart failure (CHF) phase III or IV or CHF requiring hospitalization within
             the last 6 months prior to screening

          -  Transmural myocardial (MI) infarction within the last 6 months prior to screening

          -  Moderate to severe respiratory failure, hepatic failure or renal failure

          -  Acute infection requiring intravenous antibiotics at the time of screening

          -  Uncontrolled bleeding disorders

          -  Uncontrolled diabetes mellitus

          -  Known to be HIV positive or have any other immunosuppressive disorder

          -  Inflammatory diseases of the perineal skin

          -  Urinary tract infection or acute or chronic prostatitis

          -  Uncontrolled moderate to severe urinary disorders

          -  Active inflammatory bowel disease or moderate to severe gastrointestinal (GI)
             disorders

          -  Known or suspected rectal carcinoma

          -  Subjects after anterior resection of rectum or after rectal amputation

          -  Concurrent participation in any other clinical study

        Intra-operative exclusion criteria:

          -  Irregular findings by the implanting physician before or during implantation that to
             the best of the implanting physician may lead to prostate compliance leading to
             urinary retention or other such symptoms.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yossi Muncher, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>BioProtect</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University School of Medicine, Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <results_first_submitted>July 20, 2018</results_first_submitted>
  <results_first_submitted_qc>November 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>radiation</keyword>
  <keyword>biodegradable implantable balloon</keyword>
  <keyword>intrarectal balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Balloon Implantation</title>
          <description>One arm study only
implantation of an absorbable perirectal spacer balloon
balloon implant: Absorbable perirectal spacer implantation
Balloon implantation: Implantation of the balloon between the prostate and the anterior rectal wall</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Balloon Implantation</title>
          <description>implantation of an absorbable perirectal spacer balloon
balloon implant: Absorbable perirectal spacer implantation
Balloon implantation: Implantation of the balloon between the prostate and the anterior rectal wall</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum Receiving at Least 70 Gy.</title>
        <description>Evaluated in subjects with prostate cancer who underwent radiotherapy by means of IMRT and who received the ProSpace, with individual patient success defined as a reduction of at least 25% of the volume of the rectum receiving greater or equal to 70 Gy (VRectum70) when compared to pre-implantation values.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balloon Implantation</title>
            <description>implantation of an absorbable perirectal spacer balloon
balloon implant: Absorbable perirectal spacer implantation
Balloon implantation: Implantation of the balloon between the prostate and the anterior rectal wall</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum Receiving at Least 70 Gy.</title>
          <description>Evaluated in subjects with prostate cancer who underwent radiotherapy by means of IMRT and who received the ProSpace, with individual patient success defined as a reduction of at least 25% of the volume of the rectum receiving greater or equal to 70 Gy (VRectum70) when compared to pre-implantation values.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Occurrence of Grade 2 or Greater Rectal Adverse Event or Procedure Related Adverse Events.</title>
        <description>Compare the rate of occurrence of rectal adverse events and implantation procedure related adverse events in balloon and control groups.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balloon Implantation</title>
            <description>implantation of an absorbable perirectal spacer balloon
balloon implant: Absorbable perirectal spacer implantation
Balloon implantation: Implantation of the balloon between the prostate and the anterior rectal wall</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Occurrence of Grade 2 or Greater Rectal Adverse Event or Procedure Related Adverse Events.</title>
          <description>Compare the rate of occurrence of rectal adverse events and implantation procedure related adverse events in balloon and control groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>The definition used did not differ from the clintrials.gov definition. All data was reviewed for the occurrence of these events. No serious events occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Balloon Implantation</title>
          <description>implantation of an absorbable perirectal spacer balloon
balloon implant: Absorbable perirectal spacer implantation
Balloon implantation: Implantation of the balloon between the prostate and the anterior rectal wall</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Trace of blood in semen</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>Transient acute urinary retention, resolved in a few hours</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shaul Shohat</name_or_title>
      <organization>BioProtect</organization>
      <phone>+972545423774</phone>
      <email>Shaul@bioprotect.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

